Top-News
Pharmazeutika USA

Curis News

Aktie
WKN:  A3ETJD ISIN:  US2312693094 US-Symbol:  CRIS
13,60 €
+1,90 €
+16,24%
15.05.24 16:37:09
Handeln Depot/Watchlist
Aktienanzahl *
4,82 Mio.
Marktkapitalisierung *
55,89 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.10.2023

Curis News

14.05.24 - PR Newswire
Curis Announces Additional Data from TakeAim Leukemia Study
Curis Announces Additional Data from TakeAim Leukemia Study PR Newswire
10.05.24 - PR Newswire
Curis to Present Updated Data from the TakeAim Leukemia Study
Curis to Present Updated Data from the TakeAim Leukemia Study PR Newswire
07.05.24 - PR Newswire
Curis Provides First Quarter 2024 Business Update
Curis Provides First Quarter 2024 Business Update PR Newswire
30.04.24 - PR Newswire
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024 PR Newswire
05.04.24 - PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
04.04.24 - PR Newswire
Curis to Present at Upcoming Healthcare Conferences in April
Curis to Present at Upcoming Healthcare Conferences in April PR Newswire
02.04.24 - PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS) PR Newswire
08.02.24 - PR Newswire
Curis Provides Fourth Quarter 2023 Business Update
Curis Provides Fourth Quarter 2023 Business Update PR Newswire
01.02.24 - PR Newswire
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024 PR Newswire
05.01.24 - PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
12.12.23 - PR Newswire
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study PR Newswire
11.12.23 - PR Newswire
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference PR Newswire
06.12.23 - PR Newswire
Curis Announces Three Presentations at ASH
Curis Announces Three Presentations at ASH PR Newswire
05.12.23 - PR Newswire
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma PR Newswire
02.11.23 - PR Newswire
Curis Provides Third Quarter 2023 Business Update
Curis Provides Third Quarter 2023 Business Update PR Newswire
26.10.23 - PR Newswire
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023
Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023 PR Newswire
06.10.23 - PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
12.09.23 - PR Newswire
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer
Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer PR Newswire
06.09.23 - PR Newswire
Curis to Present at Upcoming Healthcare Conferences in September
Curis to Present at Upcoming Healthcare Conferences in September PR Newswire
03.08.23 - PR Newswire
Curis Provides Second Quarter 2023 Business Update
Curis Provides Second Quarter 2023 Business Update PR Newswire

Newssuche

Videos

08:55 Uhr
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »